{
    "id": 5569,
    "name": "malignant syringoma",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:5569",
    "evidence": [
        
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02978625",
            "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 5080,
                    "therapyName": "Nivolumab + Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        }
    ]
}